Early-Onset Fetal Growth Restriction
DMACDiaMedica TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Rinvecalinase Alfa (DM199) (KLK1 Protein) in Early-Onset Fetal Growth Restriction. The expected timing is based on the latest available company guidance and may change.
06/23/26:- First two patients dosed in investigator-sponsored Phase 2 early-onset FGR trial. 08/10/26:- FGR first cohort complete; topline results expected in September 2026.
Verification
Confirm timing and program details against the company announcement or filing.